IN2014DN01883A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN01883A IN2014DN01883A IN1883DEN2014A IN2014DN01883A IN 2014DN01883 A IN2014DN01883 A IN 2014DN01883A IN 1883DEN2014 A IN1883DEN2014 A IN 1883DEN2014A IN 2014DN01883 A IN2014DN01883 A IN 2014DN01883A
- Authority
- IN
- India
- Prior art keywords
- pyridin
- chlorophenyl
- pyrazolo
- pyrrolo
- piperidin
- Prior art date
Links
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 18
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 6
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 abstract 3
- 229940113083 morpholine Drugs 0.000 abstract 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 abstract 2
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 abstract 2
- QATYRYIZQCZJPK-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-piperidin-4-ylpyrrolo[2,3-c]pyridin-4-ol Chemical compound C1=2C(O)=CN=CC=2N(C=2C=CC(Cl)=CC=2)C=C1C1CCNCC1 QATYRYIZQCZJPK-UHFFFAOYSA-N 0.000 abstract 1
- YZXLJBAURSYRBM-UHFFFAOYSA-N 5-amino-1-[4-[1-(4-chlorophenyl)pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl]pentan-1-one Chemical compound C1CN(C(=O)CCCCN)CCC1C(C1=CC=NC=C11)=CN1C1=CC=C(Cl)C=C1 YZXLJBAURSYRBM-UHFFFAOYSA-N 0.000 abstract 1
- 102100027159 Membrane primary amine oxidase Human genes 0.000 abstract 1
- 101710132836 Membrane primary amine oxidase Proteins 0.000 abstract 1
- KRGICSYONBDZHH-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]piperidin-2-yl]-piperazin-1-ylmethanone Chemical compound C1=CC(Cl)=CC=C1N1C2=CN=CC=C2C(N2C(CCCC2)C(=O)N2CCNCC2)=N1 KRGICSYONBDZHH-UHFFFAOYSA-N 0.000 abstract 1
- NMUZEXQMQNXYNZ-UHFFFAOYSA-N [4-[1-(4-chlorophenyl)pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl]-piperazin-1-ylmethanone Chemical compound C1=CC(Cl)=CC=C1N1C2=CN=CC=C2C(C2CCN(CC2)C(=O)N2CCNCC2)=C1 NMUZEXQMQNXYNZ-UHFFFAOYSA-N 0.000 abstract 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 abstract 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 abstract 1
- YPSPPJRTCRMQGD-UHFFFAOYSA-N morpholine-3-carboxamide Chemical compound NC(=O)C1COCCN1 YPSPPJRTCRMQGD-UHFFFAOYSA-N 0.000 abstract 1
- NYDFDDONODKIFA-UHFFFAOYSA-N n-(2-aminoethyl)-1-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-carboxamide Chemical compound NCCNC(=O)C1CCCCN1C(C1=CC=NC=C11)=NN1C1=CC=C(Cl)C=C1 NYDFDDONODKIFA-UHFFFAOYSA-N 0.000 abstract 1
- NQEUXJIRFMCWBP-UHFFFAOYSA-N n-(2-aminoethyl)-1-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NCCN)CCN1C(C1=CC=NC=C11)=NN1C1=CC=C(Cl)C=C1 NQEUXJIRFMCWBP-UHFFFAOYSA-N 0.000 abstract 1
- QILNKYDVBQWLTA-UHFFFAOYSA-N n-butyl-1-(4-chlorophenyl)-n-methylpyrazolo[3,4-c]pyridin-3-amine Chemical compound C12=CN=CC=C2C(N(C)CCCC)=NN1C1=CC=C(Cl)C=C1 QILNKYDVBQWLTA-UHFFFAOYSA-N 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2011/065967 WO2013037411A1 (en) | 2011-09-14 | 2011-09-14 | New enzyme inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN01883A true IN2014DN01883A (pl) | 2015-05-15 |
Family
ID=44677871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1883DEN2014 IN2014DN01883A (pl) | 2011-09-14 | 2011-09-14 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9150574B2 (pl) |
| EP (1) | EP2755974A1 (pl) |
| JP (1) | JP5796130B2 (pl) |
| CN (1) | CN103889983B (pl) |
| AU (1) | AU2011376717A1 (pl) |
| BR (1) | BR112014005793A2 (pl) |
| CA (1) | CA2847193A1 (pl) |
| EA (1) | EA201490451A1 (pl) |
| IL (1) | IL231353A0 (pl) |
| IN (1) | IN2014DN01883A (pl) |
| SG (1) | SG11201400277VA (pl) |
| WO (1) | WO2013037411A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201304526D0 (en) * | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| GB201304527D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| AU2014279863A1 (en) | 2013-06-12 | 2016-01-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| GB201416444D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New compounds |
| GB201416446D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New enzyme inhibitor compounds |
| GB201507031D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | New pharmaceutical salt forms |
| US20180360808A1 (en) | 2015-12-07 | 2018-12-20 | Benevolentai Cambridge Limited | Vap-1 inhibitors for treating pain |
| JP2020505333A (ja) * | 2017-01-09 | 2020-02-20 | アルデリックス， インコーポレイテッド | Ｎｈｅ媒介性アンチポートの阻害薬 |
| AU2019329835B2 (en) * | 2018-08-27 | 2025-05-29 | Spinogenix, Inc. | Fascin binding compounds for spinogenesis |
| EP3976610A1 (en) | 2019-05-29 | 2022-04-06 | Syngenta Crop Protection AG | Microbiocidal derivatives |
| AU2020404305A1 (en) | 2019-12-19 | 2022-08-04 | Janssen Pharmaceutica Nv | Substituted straight chain spiro derivatives |
| JP2023521468A (ja) * | 2020-04-16 | 2023-05-24 | エフ． ホフマン－ラ ロシュ アーゲー | ビフェニル誘導体 |
| PE20242359A1 (es) | 2021-06-01 | 2024-12-16 | Janssen Pharmaceutica Nv | Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos |
| WO2023193790A1 (en) * | 2022-04-08 | 2023-10-12 | Janssen Pharmaceutica Nv | Crystalline forms of an inhibitor of the menin/mll interaction |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| DE19649460A1 (de) | 1996-11-26 | 1998-05-28 | Bayer Ag | Neue substituierte Pyrazolderivate |
| ATE247110T1 (de) | 1999-09-14 | 2003-08-15 | Aventis Pharma Inc | Benzisoxazolyl-, pyridoisoxazolyl- und benzthienyl-phenoxy derivate als d4 antagonisten |
| WO2002038153A1 (en) | 2000-11-09 | 2002-05-16 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives |
| US6982286B2 (en) | 2001-07-12 | 2006-01-03 | Biotie Therapies Corp. | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| EP1432714B1 (en) | 2001-10-02 | 2008-08-06 | Smithkline Beecham Corporation | Chemical compounds |
| US7456169B2 (en) | 2003-02-27 | 2008-11-25 | Abbott Laboratories Inc. | Heterocyclic kinase inhibitors |
| WO2005014530A2 (en) | 2003-08-08 | 2005-02-17 | La Jolla Pharmaceutical Co. | Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment of diseases |
| JP5069907B2 (ja) | 2003-09-17 | 2012-11-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 縮合複素環式化合物 |
| CA2553724A1 (en) | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| ATE524467T1 (de) | 2005-04-25 | 2011-09-15 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
| EA017278B9 (ru) | 2005-06-22 | 2013-01-30 | Кемосентрикс, Инк. | Соединения азаиндазола и способы применения |
| WO2007120528A2 (en) | 2006-03-31 | 2007-10-25 | La Jolla Pharmaceutical Company | Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases |
| BRPI0710527B8 (pt) | 2006-04-04 | 2021-05-25 | Fibrogen Inc | compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende |
| GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
| WO2008088744A1 (en) | 2007-01-17 | 2008-07-24 | Merck & Co., Inc. | Decahydroquinoline analogs as cb2 receptor modulators |
| JP2010525032A (ja) | 2007-05-02 | 2010-07-22 | ノバルティス アーゲー | ヘテロ環化合物及び殺有害生物剤としてのそれらの使用 |
| GB0725103D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Novel compounds |
| CA2712701A1 (en) | 2008-01-31 | 2009-08-06 | Henning Steinhagen | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals |
| WO2009108551A2 (en) * | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
| WO2010031791A1 (en) * | 2008-09-16 | 2010-03-25 | Biovitrum Ab (Publ) | New compounds ii |
| EP2334672B1 (en) | 2008-09-16 | 2013-11-20 | Proximagen Limited | 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine compounds as inhibitors of SSAO |
| ES2403633T3 (es) | 2008-12-04 | 2013-05-20 | Proximagen Limited | Compuestos de imidazopiridina |
| JP2012211085A (ja) | 2009-08-12 | 2012-11-01 | Kyowa Hakko Kirin Co Ltd | ヘッジホッグシグナル阻害剤 |
| GB201004311D0 (en) * | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| GB201115853D0 (en) | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
-
2011
- 2011-09-14 EA EA201490451A patent/EA201490451A1/ru unknown
- 2011-09-14 AU AU2011376717A patent/AU2011376717A1/en not_active Abandoned
- 2011-09-14 SG SG11201400277VA patent/SG11201400277VA/en unknown
- 2011-09-14 BR BR112014005793A patent/BR112014005793A2/pt not_active IP Right Cessation
- 2011-09-14 US US14/344,417 patent/US9150574B2/en not_active Expired - Fee Related
- 2011-09-14 JP JP2014530103A patent/JP5796130B2/ja not_active Expired - Fee Related
- 2011-09-14 IN IN1883DEN2014 patent/IN2014DN01883A/en unknown
- 2011-09-14 WO PCT/EP2011/065967 patent/WO2013037411A1/en not_active Ceased
- 2011-09-14 CA CA2847193A patent/CA2847193A1/en not_active Abandoned
- 2011-09-14 EP EP11761040.2A patent/EP2755974A1/en not_active Withdrawn
- 2011-09-14 CN CN201180073402.9A patent/CN103889983B/zh not_active Expired - Fee Related
-
2014
- 2014-03-06 IL IL231353A patent/IL231353A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103889983A (zh) | 2014-06-25 |
| US9150574B2 (en) | 2015-10-06 |
| IL231353A0 (en) | 2014-04-30 |
| JP5796130B2 (ja) | 2015-10-21 |
| EA201490451A1 (ru) | 2014-12-30 |
| AU2011376717A1 (en) | 2014-03-20 |
| US20140357623A1 (en) | 2014-12-04 |
| JP2015502913A (ja) | 2015-01-29 |
| BR112014005793A2 (pt) | 2017-03-28 |
| CA2847193A1 (en) | 2013-03-21 |
| EP2755974A1 (en) | 2014-07-23 |
| SG11201400277VA (en) | 2014-05-29 |
| WO2013037411A1 (en) | 2013-03-21 |
| CN103889983B (zh) | 2015-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN01883A (pl) | ||
| RU2018115722A (ru) | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ | |
| US11168090B2 (en) | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | |
| DK2627649T3 (en) | CXCR4 receptor antagonists | |
| JP2012508776A5 (pl) | ||
| RU2012113593A (ru) | Ингибиторы jak | |
| EP3523302A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| AR102852A1 (es) | Inhibidores heterocíclicos de la calicreína plasmática | |
| US11472802B2 (en) | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors | |
| NO20061528L (no) | Polymrofe former av 3-(4-amino-1-okso-1,3dihydro-isoindol-2-yl)-piperidin-2,6-dion | |
| SI2046331T1 (sl) | Uporaba 3-(4-amino-1-okso-1,3-dihidro-izoindol-2-il)-piperidin-2,6-diona za zdravljenje limfoma plaščnih celic | |
| JP2006503866A5 (pl) | ||
| ZA201000212B (en) | Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treatment of inflammation | |
| HRP20120240T1 (hr) | Piridil piperidin antagonisti receptora za oreksin | |
| JP2016519096A5 (pl) | ||
| NZ594765A (en) | Anthelmintic agents and their use | |
| HRP20130054T1 (hr) | Spojevi pirazina kao inhibitori fosfodiesteraze 10 | |
| JP2012528137A5 (pl) | ||
| UA94928C2 (en) | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine | |
| SG120286A1 (en) | Cushion for packing disks such as semiconductor wafers | |
| AU2010224865A1 (en) | Piperidine derivatives as NK3 receptor antagonists | |
| MY147474A (en) | 1-[(4-[benzoyl(methyl)amino]-3-(phenyl)butyl]azetidine derivatives for the treatment of gastrointestinal disorders 1 | |
| TW200617000A (en) | Methods of making 2,6-diaryl piperidine derivatives | |
| RU2013102399A (ru) | Производные (3-метилпирролидин-3-ил)-метил пиридинилового эфира и их применение в качестве антагонистов рецептора nk-3 | |
| JP2019517563A5 (pl) |